The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

Risk groups have been identified and validated that predict PSAD and OS in men with mCRPC and may facilitate evaluation of new systemic regimens warranting definitive testing in comparison with docetaxel and prednisone. Prospective validation of this classification system is needed.